Ascorbic acid: a promising agent in chronic kidney disease?

Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is related with impaired endothelial function and poor outcomes in chronic kidney disease (CKD) patients. In addition, oxidative stress and inflammation are also a common problem in CKD patients, and both have an impo...

Descripción completa

Detalles Bibliográficos
Autores principales: Karahan, Salih, Afsar, Baris, Kanbay, Mehmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Cardiovascular Disease in CKD
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070088/
https://www.ncbi.nlm.nih.gov/pubmed/30094017
http://dx.doi.org/10.1093/ckj/sfy044
_version_ 1783343619443261440
author Karahan, Salih
Afsar, Baris
Kanbay, Mehmet
author_facet Karahan, Salih
Afsar, Baris
Kanbay, Mehmet
author_sort Karahan, Salih
collection PubMed
description Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is related with impaired endothelial function and poor outcomes in chronic kidney disease (CKD) patients. In addition, oxidative stress and inflammation are also a common problem in CKD patients, and both have an important role in the development and progression of atherosclerosis and increased cardiovascular events in CKD. Ascorbic acid might be a promising agent in CKD for improving outcome by decreasing oxidative stress and ADMA levels.
format Online
Article
Text
id pubmed-6070088
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-60700882018-08-09 Ascorbic acid: a promising agent in chronic kidney disease? Karahan, Salih Afsar, Baris Kanbay, Mehmet Clin Kidney J Cardiovascular Disease in CKD Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is related with impaired endothelial function and poor outcomes in chronic kidney disease (CKD) patients. In addition, oxidative stress and inflammation are also a common problem in CKD patients, and both have an important role in the development and progression of atherosclerosis and increased cardiovascular events in CKD. Ascorbic acid might be a promising agent in CKD for improving outcome by decreasing oxidative stress and ADMA levels. Oxford University Press 2018-08 2018-06-26 /pmc/articles/PMC6070088/ /pubmed/30094017 http://dx.doi.org/10.1093/ckj/sfy044 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Cardiovascular Disease in CKD
Karahan, Salih
Afsar, Baris
Kanbay, Mehmet
Ascorbic acid: a promising agent in chronic kidney disease?
title Ascorbic acid: a promising agent in chronic kidney disease?
title_full Ascorbic acid: a promising agent in chronic kidney disease?
title_fullStr Ascorbic acid: a promising agent in chronic kidney disease?
title_full_unstemmed Ascorbic acid: a promising agent in chronic kidney disease?
title_short Ascorbic acid: a promising agent in chronic kidney disease?
title_sort ascorbic acid: a promising agent in chronic kidney disease?
topic Cardiovascular Disease in CKD
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070088/
https://www.ncbi.nlm.nih.gov/pubmed/30094017
http://dx.doi.org/10.1093/ckj/sfy044
work_keys_str_mv AT karahansalih ascorbicacidapromisingagentinchronickidneydisease
AT afsarbaris ascorbicacidapromisingagentinchronickidneydisease
AT kanbaymehmet ascorbicacidapromisingagentinchronickidneydisease

Ejemplares similares